BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16517569)

  • 1. Pegylated interferon and ribavirin in haemodialysis patients.
    Bruchfeld A; Lindahl K; Reichard O; Carlsson T; Schvarcz R
    Nephrol Dial Transplant; 2006 May; 21(5):1444-5; author reply 1445-6. PubMed ID: 16517569
    [No Abstract]   [Full Text] [Related]  

  • 2. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
    Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
    J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
    Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
    J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis C treatment. Side effects and their management.
    Shobokshi OA; Tantawe AO; Al-Kayyal BM
    Saudi Med J; 2003 Jul; 24 Suppl 2():S76-8. PubMed ID: 12897905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
    [No Abstract]   [Full Text] [Related]  

  • 8. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy.
    Deltenre P; Moreno C; Tran A; Ollivier I; Provôt F; Stanke F; Lazrek M; Castel H; Canva V; Louvet A; Colin M; Glowacki F; Dharancy S; Henrion J; Hazzan M; Noel C; Mathurin P
    Aliment Pharmacol Ther; 2011 Aug; 34(4):454-61. PubMed ID: 21682756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin.
    Formann E; Stauber R; Denk DM; Jessner W; Zollner G; Munda-Steindl P; Gangl A; Ferenci P
    Am J Gastroenterol; 2004 May; 99(5):873-7. PubMed ID: 15128353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.
    Bruchfeld A; Lindahl K; Reichard O; Carlsson T; Schvarcz R
    J Viral Hepat; 2006 May; 13(5):316-21. PubMed ID: 16637862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.
    Alfaleh FZ; Hadad Q; Khuroo MS; Aljumah A; Algamedi A; Alashgar H; Al-Ahdal MN; Mayet I; Khan MQ; Kessie G
    Liver Int; 2004 Dec; 24(6):568-74. PubMed ID: 15566506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
    von Wagner M; Huber M; Berg T; Hinrichsen H; Rasenack J; Heintges T; Bergk A; Bernsmeier C; Häussinger D; Herrmann E; Zeuzem S
    Gastroenterology; 2005 Aug; 129(2):522-7. PubMed ID: 16083709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.
    Baker DE
    Rev Gastroenterol Disord; 2003; 3(2):93-109. PubMed ID: 12776006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.
    Hasan F; Asker H; Al-Khaldi J; Siddique I; Al-Ajmi M; Owaid S; Varghese R; Al-Nakib B
    Am J Gastroenterol; 2004 Sep; 99(9):1733-7. PubMed ID: 15330911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan.
    Yu ML; Dai CY; Lin ZY; Lee LP; Hou NJ; Hsieh MY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Liver Int; 2006 Feb; 26(1):73-81. PubMed ID: 16420512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C.
    Berg T; Naumann U; Wiedenmann B; Hopf U
    Z Gastroenterol; 2001 Feb; 39(2):145-51. PubMed ID: 11253505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.